Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of $184.91 billion. The enterprise value is $197.86 billion.
| Market Cap | 184.91B |
| Enterprise Value | 197.86B |
Important Dates
The last earnings date was Tuesday, February 10, 2026, after market close.
| Earnings Date | Feb 10, 2026 |
| Ex-Dividend Date | Mar 13, 2026 |
Share Statistics
Gilead Sciences has 1.24 billion shares outstanding.
| Current Share Class | 1.24B |
| Shares Outstanding | 1.24B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 89.34% |
| Float | 1.24B |
Valuation Ratios
The trailing PE ratio is 21.97 and the forward PE ratio is 17.15. Gilead Sciences's PEG ratio is 1.14.
| PE Ratio | 21.97 |
| Forward PE | 17.15 |
| PS Ratio | 6.28 |
| Forward PS | 6.00 |
| PB Ratio | 8.14 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 19.55 |
| P/OCF Ratio | 18.46 |
| PEG Ratio | 1.14 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.57, with an EV/FCF ratio of 20.92.
| EV / Earnings | 23.25 |
| EV / Sales | 6.72 |
| EV / EBITDA | 13.57 |
| EV / EBIT | 16.74 |
| EV / FCF | 20.92 |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.13.
| Current Ratio | 1.55 |
| Quick Ratio | 1.23 |
| Debt / Equity | 1.13 |
| Debt / EBITDA | 1.73 |
| Debt / FCF | 2.70 |
| Interest Coverage | 11.54 |
Financial Efficiency
Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 26.86%.
| Return on Equity (ROE) | 40.66% |
| Return on Assets (ROA) | 12.52% |
| Return on Invested Capital (ROIC) | 26.86% |
| Return on Capital Employed (ROCE) | 25.03% |
| Weighted Average Cost of Capital (WACC) | 6.03% |
| Revenue Per Employee | $1.73M |
| Profits Per Employee | $500,588 |
| Employee Count | 17,000 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 3.58 |
Taxes
In the past 12 months, Gilead Sciences has paid $1.29 billion in taxes.
| Income Tax | 1.29B |
| Effective Tax Rate | 13.13% |
Stock Price Statistics
The stock price has increased by +34.85% in the last 52 weeks. The beta is 0.39, so Gilead Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | +34.85% |
| 50-Day Moving Average | 135.25 |
| 200-Day Moving Average | 120.13 |
| Relative Strength Index (RSI) | 56.66 |
| Average Volume (20 Days) | 7,833,017 |
Short Selling Information
The latest short interest is 21.89 million, so 1.76% of the outstanding shares have been sold short.
| Short Interest | 21.89M |
| Short Previous Month | 23.68M |
| Short % of Shares Out | 1.76% |
| Short % of Float | 1.77% |
| Short Ratio (days to cover) | 2.57 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of $29.44 billion and earned $8.51 billion in profits. Earnings per share was $6.78.
| Revenue | 29.44B |
| Gross Profit | 23.21B |
| Operating Income | 11.82B |
| Pretax Income | 9.80B |
| Net Income | 8.51B |
| EBITDA | 14.58B |
| EBIT | 11.82B |
| Earnings Per Share (EPS) | $6.78 |
Balance Sheet
The company has $9.61 billion in cash and $25.54 billion in debt, with a net cash position of -$12.95 billion or -$10.43 per share.
| Cash & Cash Equivalents | 9.61B |
| Total Debt | 25.54B |
| Net Cash | -12.95B |
| Net Cash Per Share | -$10.43 |
| Equity (Book Value) | 22.62B |
| Book Value Per Share | 18.29 |
| Working Capital | 6.53B |
Cash Flow
In the last 12 months, operating cash flow was $10.02 billion and capital expenditures -$563.00 million, giving a free cash flow of $9.46 billion.
| Operating Cash Flow | 10.02B |
| Capital Expenditures | -563.00M |
| Free Cash Flow | 9.46B |
| FCF Per Share | $7.62 |
Margins
Gross margin is 78.84%, with operating and profit margins of 40.14% and 28.90%.
| Gross Margin | 78.84% |
| Operating Margin | 40.14% |
| Pretax Margin | 33.27% |
| Profit Margin | 28.90% |
| EBITDA Margin | 49.51% |
| EBIT Margin | 40.14% |
| FCF Margin | 32.12% |
Dividends & Yields
This stock pays an annual dividend of $3.28, which amounts to a dividend yield of 2.28%.
| Dividend Per Share | $3.28 |
| Dividend Yield | 2.28% |
| Dividend Growth (YoY) | 2.90% |
| Years of Dividend Growth | 11 |
| Payout Ratio | 47.05% |
| Buyback Yield | 0.24% |
| Shareholder Yield | 2.44% |
| Earnings Yield | 4.60% |
| FCF Yield | 5.11% |
Analyst Forecast
The average price target for Gilead Sciences is $143.50, which is -3.66% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $143.50 |
| Price Target Difference | -3.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 4.57% |
| EPS Growth Forecast (5Y) | 12.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 28, 2013. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 28, 2013 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Gilead Sciences has an Altman Z-Score of 3.9 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.9 |
| Piotroski F-Score | 7 |